Mod­er­na strikes $1.8B can­cer re­search deal with Im­mat­ics 

Mod­er­na has inked a deal worth up to $1.8 bil­lion with TCR spe­cial­ist Im­mat­ics that broad­ens the com­pa­ny’s po­si­tion in mR­NA-based can­cer re­search.

The Cam­bridge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER